Merck & Co., Inc. (MRK) Shares Sold by Cambridge Trust Co.
Cambridge Trust Co. lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 5.1% in the 4th quarter, Holdings Channel reports. The firm owned 529,366 shares of the company’s stock after selling 28,658 shares during the period. Merck & Co., Inc. accounts for 1.9% of Cambridge Trust Co.’s investment portfolio, making the stock its 13th largest holding. Cambridge Trust Co.’s holdings in Merck & Co., Inc. were worth $29,787,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Walter & Keenan Financial Consulting Co. MI ADV grew its stake in Merck & Co., Inc. by 11.8% during the 4th quarter. Walter & Keenan Financial Consulting Co. MI ADV now owns 41,613 shares of the company’s stock valued at $2,342,000 after acquiring an additional 4,406 shares in the last quarter. Pratt Collard Advisory Partners LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $1,148,000. MHI Funds LLC purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $2,853,000. WoodTrust Financial Corp purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $2,368,000. Finally, Terril Brothers Inc. purchased a new stake in Merck & Co., Inc. during the 4th quarter valued at about $14,045,000. Hedge funds and other institutional investors own 72.65% of the company’s stock.
Several analysts have recently weighed in on the stock. Sanford C. Bernstein reissued a “buy” rating and issued a $64.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, November 15th. SunTrust Banks raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and increased their price target for the company from $54.00 to $72.00 in a research note on Tuesday, January 16th. BMO Capital Markets set a $68.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Tuesday, January 16th. ValuEngine raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th. Finally, Bank of America assumed coverage on shares of Merck & Co., Inc. in a research note on Tuesday, November 28th. They issued a “buy” rating and a $64.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eleven have given a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Hold” and a consensus price target of $66.41.
Merck & Co., Inc. (MRK) opened at $54.36 on Monday. The company has a current ratio of 1.33, a quick ratio of 1.16 and a debt-to-equity ratio of 0.62. The firm has a market cap of $146,560.00, a P/E ratio of 29.87, a P/E/G ratio of 2.24 and a beta of 0.81. Merck & Co., Inc. has a 1 year low of $53.12 and a 1 year high of $66.78.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.04. The firm had revenue of $10.43 billion during the quarter, compared to analysts’ expectations of $10.48 billion. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the company posted $0.89 EPS. analysts expect that Merck & Co., Inc. will post 4.16 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 6th. Investors of record on Thursday, March 15th will be given a dividend of $0.48 per share. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.53%. Merck & Co., Inc.’s payout ratio is currently 105.49%.
Merck & Co., Inc. announced that its board has initiated a share buyback program on Tuesday, November 28th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
COPYRIGHT VIOLATION NOTICE: “Merck & Co., Inc. (MRK) Shares Sold by Cambridge Trust Co.” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2018/03/05/merck-co-inc-mrk-shares-sold-by-cambridge-trust-co.html.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.